Find a Doctor Search
Dr. Andrew (Andy) Brohl is a medical oncologist and physician-scientist. His clinical interest is in the care of patients with a diagnosis of sarcoma or a cutaneous (skin) malignancy, including melanoma. Dr. Brohl’s laboratory research focuses on the utilization of genomics and other high-throughput technologies to learn more about rare cancers and for clinically translational applications. Examples of his current projects include genomic analysis of rare cancer subtypes, identification of drug targets from “-omics” datatypes, application of genomics for personalized cancer therapy, and development of non-invasive molecular profiling technology. Additionally, he is a member of the analysis team for the National Institutes of Health’s “The Cancer Genome Atlas” (TCGA) sarcoma project. Dr. Brohl earned his MD degree from the University of Miami, Miller School of Medicine. He completed an Internal Medicine Residency at Georgetown University and a Hematology and Medical Oncology Fellowship at the National Cancer Institute. He joined Moffitt in 2015 from the Icahn School of Medicine at Mount Sinai where he held dual academic appointments in the Department of Genetics and Genomic Science and the Division of Hematology and Medical Oncology. Dr. Brohl has received numerous academic awards including graduation with research distinction and magna cum laude from Duke University. Also while at Duke, he was named to the Tau Beta Pi engineering honor society, was selected as a Pratt Engineering Undergraduate Fellow, and graduated with dual majors in Biomedical Engineering and Mathematics. During medical school, he was recognized for academic and service contributions, including post-Hurricane Katrina volunteer efforts in southern Mississippi, and was named to the Alpha Omega Alpha medical honor society. Dr. Brohl is currently a member of several professional associations, including the American Association for Cancer Research, Connective Tissue Oncology Society, the Society for Immunotherapy of Cancer, and the American Society of Clinical Oncology.
Education & Training
- Medical Oncology
- National Cancer Institute - Hematology and Oncology
- Georgetown University - Internal Medicine
- University of Miami Miller School of Medicine - MD
CLINICAL TRIAL 17938
A Phase II, Open-label, Multicenter Trial to Investigate the Clinical Activity and Safety of MSB0010718C in Subjects with Merkel Cell Carcinoma
Intervention: MSB00100718C (Avelumab); Not Applicable
CLINICAL TRIAL 18821
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients with Potentially Resectable Soft Tissue Sarcoma Treated with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin Combination Therapy
Intervention: Adriamycin (doxorubicin); Olaratumab; doxorubicin
CLINICAL TRIAL 19003
A Randomized Phase 3 Trial of TRC105 and Pazopanib versus Pazopanib Alone In Patients with Advanced Angiosarcoma (TAPPAS)
Intervention: Pazopanib; TRC105
CLINICAL TRIAL 17937
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma
Intervention: BMS-936558 (Nivolumab); Nivolumab; Not Applicable; Urelumab
CLINICAL TRIAL 18613
Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Intervention: Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); gemcitabine
CLINICAL TRIAL 18855
Multicenter, Open-label, Phase 1, Dose-escalation,Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
Intervention: KHK2455; KW-0761 (Mogamulizumab); Mogamulizumab
CLINICAL TRIAL 17974
An Open-Label, Multicenter, Dose-Escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; RTA 408; Yervoy (Ipilimumab)
CLINICAL TRIAL 18119
A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Intervention: G100; G305; LV305; cyclophosphamide; cytoxan (cyclophosphamide)
CLINICAL TRIAL 18350
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients with Synovial Sarcoma
Intervention: MESNA; NY-ESO-1c259T; Neupogen (filgrastim); cyclophosphamide; cytoxan (cyclophosphamide); filgrastim; fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 18916
A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance
Intervention: 748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib)
CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-042
CLINICAL TRIAL 18874
A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)
Intervention: BMS-936558 (Nivolumab); HBI-8000 (chidamide); Nivolumab
CLINICAL TRIAL 18786
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
CLINICAL TRIAL 18377
A Pilot Clinical Trial Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2; Nivolumab; Proleukin (Interleukin-2); TIL
CLINICAL TRIAL 18933
Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Intervention: Ipilimumab; Pembrolizumab (Keytruda); Yervoy (Ipilimumab)
CLINICAL TRIAL 18975
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
CLINICAL TRIAL 18597
Phase I Study of Escalating Doses of XL888 with Vemurafenib plus Cobimetinib for Patients with Unresectable BRAF Mutated Stage III/IV Melanoma
Intervention: Cobimetinib; RO5185426 (Vemurafenib); Vemurafenib (Zelboraf); XL888
CLINICAL TRIAL 19310
A Phase III, Open-Label, Multicenter,Two-Arm, Randomized Study To Investigate The Efficacy And Safety Of Cobimetinib Plus Atezolizumab Versus Pembrolizumab In Patients With Previously Untreated Advanced Brafv600 Wild-Type Melanoma
Intervention: Atezolizumab (Tecentriq); Cobimetinib; Pembrolizumab (Keytruda)
If you believe you are eligible for one of these trials or studies, please call
- Borinstein SC, Steppan D, Hayashi M, Loeb DM, Isakoff MS, Binitie O, Brohl AS, Bridge JA, Stavas M, Shinohara ET, Meyer WH, Reed DR, Wagner LM. Consensus and controversies regarding the treatment of rhabdomyosarcoma. Pediatr Blood Cancer. 2017 Sep. Pubmedid: 28905489.
- Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2017 Oct. Pubmedid: 29045547.
- Snyder M, Gangadhara S, Brohl AS, Ludlow S, Nanjappa S. Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue. Cancer Control. 2017 Oct;24(5). Pubmedid: 28975823.
- Brohl AS, Kahen E, Yoder SJ, Teer JK, Reed DR. The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Sci Rep. 2017 Nov;7(1):14992. Pubmedid: 29118384. Pmcid: PMC5678116.
- Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS, Shinohara ET, Bridge JA, Loeb DM, Borinstein SC, Isakoff MS. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer. 2017 Jun;123(12):2206-2218. Pubmedid: 28323337. Pmcid: PMC5485018.
- Brohl AS, Patidar R, Turner CE, Wen X, Song YK, Wei JS, Calzone KA, Khan J. Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. Genet Med. 2017 Aug;19(8):955-958. Pubmedid: 28125078. Pmcid: PMC5529247.
- Hoggard TM, Henderson-Jackson E, Bui MM, Caracciolo J, Teer JK, Yoder S, Binitie O, Gonzalez RJ, Brohl AS, Reed DR. Myoepithelial carcinoma with RB1 mutation: remarkable chemosensitivity to carcinoma of unknown origin therapy. BMC Cancer. 2017 Apr;17(1):250. Pubmedid: 28390395. Pmcid: PMC5385017.
- Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA, Sarin R, Blay JY, O'Donoghue SI, Thomas DM. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016 Sep;17(9):1261-1271. Pubmedid: 27498913.
- Kothari N, Teer JK, Abbott AM, Srikumar T, Zhang Y, Yoder SJ, Brohl AS, Kim RD, Reed DR, Shibata D. Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers. Cancer. 2016 Sep;122(18):2828-2835. Pubmedid: 27244218. Pmcid: PMC5014625.
- Uzilov AV, Ding W, Fink MY, Antipin Y, Brohl AS, Davis C, Lau CY, Pandya C, Shah H, Kasai Y, Powell J, Micchelli M, Castellanos R, Zhang Z, Linderman M, Kinoshita Y, Zweig M, Raustad K, Cheung K, Castillo D, Wooten M, Bourzgui I, Newman LC, Deikus G, Mathew B, Zhu J, Glicksberg BS, Moe AS, Liao J, Edelmann L, Dudley JT, Maki RG, Kasarskis A, Holcombe RF, Mahajan M, Hao K, Reva B, Longtine J, Starcevic D, Sebra R, Donovan MJ, Li S, Schadt EE, Chen R. Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Med. 2016 Jun;8(1):62. Pubmedid: 27245685. Pmcid: PMC4888213.
- Brohl AS, Khushalani NI, Eroglu Z, Markowitz J, Thapa R, Chen YA, Kudchadkar R, Weber JS. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Immunother Cancer. 2016 Dec;4:85. Pubmedid: 28031816. Pmcid: PMC5170897.
- Chang W, Brohl A, Patidar R, Sindiri S, Shern JF, Wei JS, Song YK, Yohe ME, Gryder BE, Zhang S, Calzone KA, Shivaprasad N, Wen X, Badgett T, Miettinen M, Hartman KR, League-Pascual JC, Trahair T, Widemann BC, Merchant MS, Kaplan RN, Lin JC, Khan J. MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research. Clin Cancer Res. 2016 Aug;22(15):3810-3820. Pubmedid: 26994145. Pmcid: PMC4970946.
- Brohl AS, Demicco EG, Mourtzikos K, Maki RG. Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation. Clin Sarcoma Res. 2015 Sep;5:21. Pubmedid: 26396737. Pmcid: PMC4578851.
- Brock CO, Brohl AS, Običan SG. Incidence, pathophysiology, and clinical manifestations of antiphospholipid syndrome. Birth Defects Res C Embryo Today. 2015 Sep;105(3):201-208. Pubmedid: 26396056.
- Brohl AS, Stinson JR, Su HC, Badgett T, Jennings CD, Sukumar G, Sindiri S, Wang W, Kardava L, Moir S, Dalgard CL, Moscow JA, Khan J, Snow AL. Germline CARD11 Mutation in a Patient with Severe Congenital B Cell Lymphocytosis. J Clin Immunol. 2015 Jan;35(1):32-46. Pubmedid: 25352053. Pmcid: PMC4466218.
- Brohl AS, Li L, Andikyan V, Običan SG, Cioffi A, Hao K, Dudley JT, Ascher-Walsh C, Kasarskis A, Maki RG. Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. Oncologist. 2015 Apr;20(4):433-439. Pubmedid: 25765878. Pmcid: PMC4391766.
- Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, Patidar R, Hurd L, Chen L, Shern JF, Liao H, Wen X, Gerard J, Kim JS, Lopez Guerrero JA, Machado I, Wai DH, Picci P, Triche T, Horvai AE, Miettinen M, Wei JS, Catchpool D, Llombart-Bosch A, Waldman T, Khan J. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014 Jul;10(7):e1004475. Pubmedid: 25010205. Pmcid: PMC4091782.
- Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014 Feb;4(2):216-231. Pubmedid: 24436047. Pmcid: PMC4462130.
- Solomon DA, Brohl AS, Khan J, Miettinen M. Clinicopathologic features of a second patient with Ewing-like sarcoma harboring CIC-FOXO4 gene fusion. Am J Surg Pathol. 2014 Dec;38(12):1724-1725. Pubmedid: 25321332. Pmcid: PMC4229425.
- Farid M, Ahn L, Brohl A, Cioffi A, Maki RG. Consumptive coagulopathy in angiosarcoma: a recurrent phenomenon?. Sarcoma. 2014 Apr;2014:617102. Pubmedid: 24693222. Pmcid: PMC3945465.
- Brohl AS, Song JY, Lieberman R, Gause B. Synchronous indolent primary gastrointestinal lymphomas managed successfully with conservative measures. Am J Ther. 2013 Mar;20(5):549-553. Pubmedid: 22020085. Pmcid: PMC3266981.